Polycystic ovary syndrome (PCOS) affects an estimated 8 to 13 percent of women of reproductive age worldwide, according to the World Health Organization. As glucagon-like peptide-1 (GLP-1) medications like semaglutide and tirzepatide have transformed the treatment of type 2 diabetes and obesity, researchers are asking a compelling question: can these drugs also help the millions of women living with PCOS?
Early clinical evidence is promising, though the story is more nuanced than social media buzz suggests. Here is what current research indicates about how GLP-1 medications may fit into PCOS care.
Understanding PCOS and Its Metabolic Roots
PCOS is a hormonal and metabolic condition characterized by irregular menstrual cycles, elevated androgens (male hormones), and often the presence of small cysts on the ovaries. It is a leading cause of infertility in women and is linked to a higher lifetime risk of type 2 diabetes, cardiovascular disease, and endometrial cancer.
Research published in the Endocrine Reviews and by the National Institutes of Health highlights that insulin resistance is a central driver of PCOS in roughly 65 to 70 percent of cases. When cells respond poorly to insulin, the pancreas releases more of it, and elevated insulin levels signal the ovaries to produce excess androgens. This cycle can worsen weight gain, disrupt ovulation, and drive many of the symptoms women find most distressing.
Standard first-line therapies include lifestyle changes, combined oral contraceptives, metformin, and ovulation-inducing medications like letrozole. For years, however, treatment options for the metabolic side of PCOS remained limited.
How GLP-1 Medications Work
GLP-1 receptor agonists, sold under brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound, mimic a natural gut hormone released after eating. According to research from the New England Journal of Medicine, these drugs enhance insulin secretion when blood sugar is elevated, slow gastric emptying, and act on brain centers that regulate hunger and satiety.
The result is often meaningful weight loss and improved glucose control. Because insulin resistance and excess weight are so tightly interwoven with PCOS, the theoretical case for using GLP-1 agonists in this population is strong.
What Research Shows About GLP-1s for PCOS
Several small trials and meta-analyses have examined GLP-1 medications, most often liraglutide and semaglutide, in women with PCOS. A 2023 systematic review published in Reproductive Biology and Endocrinology pooled data from multiple randomized studies and found that GLP-1 receptor agonists produced significantly greater weight loss and improvements in insulin sensitivity compared with metformin or lifestyle intervention alone.
A separate analysis in Frontiers in Endocrinology reported that women taking GLP-1 agonists saw reductions in waist circumference, fasting insulin, and testosterone levels, along with improvements in menstrual regularity. Trials specifically evaluating semaglutide in overweight women with PCOS have shown average weight reductions of 7 to 10 percent over several months, along with better ovulatory function.
Weight and Insulin Sensitivity
Weight loss of even 5 to 10 percent is known to improve ovulation and reduce androgen levels in women with PCOS. GLP-1 drugs appear to reliably reach this threshold in many patients, which may explain much of their benefit.
Menstrual Regularity and Fertility
Improved insulin sensitivity often translates into more regular cycles. Some studies suggest GLP-1 medications may help restore ovulation in women who have not responded to metformin or lifestyle change alone. Importantly, these drugs are not approved for use during pregnancy and must be discontinued before conception, typically several weeks in advance. Women planning pregnancy should discuss timing carefully with their clinician.
Androgen Levels
Reductions in circulating testosterone and improvements in the ratio of luteinizing hormone to follicle-stimulating hormone have been reported in some GLP-1 trials, according to research summarized by the Journal of Clinical Endocrinology and Metabolism. This may translate into fewer symptoms such as acne and unwanted hair growth over time, though larger long-term studies are still needed.
Safety Considerations and Side Effects
GLP-1 medications are not without risks. The U.S. Food and Drug Administration notes that the most common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain, particularly when the dose is being increased. Less common but more serious risks include pancreatitis, gallbladder disease, and, in animal studies, thyroid C-cell tumors. These drugs carry a boxed warning against use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
It is also important to note that GLP-1 medications are not currently approved by the FDA for the treatment of PCOS. Their use in this population is off-label, meaning a clinician is prescribing an approved drug for a condition it has not been formally studied for at scale. Access, insurance coverage, and cost remain significant barriers for many patients.
The Bigger Picture: Lifestyle Still Matters
Even as pharmacological options expand, foundational habits remain central to PCOS care. Research consistently shows that a nutrient-dense eating pattern, regular physical activity, adequate sleep, and stress management improve insulin sensitivity and reproductive outcomes. The Mediterranean and low-glycemic dietary patterns, in particular, have evidence supporting their use in PCOS, according to reviews in Nutrients and the American Journal of Clinical Nutrition.
GLP-1 medications may become a valuable tool for a subset of women with PCOS, especially those with significant insulin resistance or obesity who have not responded to other approaches. However, they are best viewed as one option within a comprehensive plan that includes nutrition, movement, sleep, and mental health support.
Anyone considering these medications should have a thorough conversation with a qualified healthcare provider about their individual risk profile, reproductive goals, and long-term care plan. Larger, longer-term trials are underway, and the next few years should bring clearer answers about where GLP-1 drugs belong in PCOS treatment.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.